SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+10.95%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$360M
AUM Growth
+$360M
(+91%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
31.22%
Top 10 Holdings %
Top 10 Hldgs %
61.27%
Holding
86
New
21
Increased
12
Reduced
26
Closed
20
Top Buys
| 1 |
BioAtla
BCAB
|
$108M |
| 2 |
Galecto
GLTO
|
$18.9M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$10.2M |
| 4 |
C4 Therapeutics
CCCC
|
$8.9M |
| 5 |
Exelixis
EXEL
|
$7.84M |
Top Sells
| 1 |
OraSure Technologies
OSUR
|
$7.61M |
| 2 |
QuidelOrtho
QDEL
|
$6.75M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
$6.49M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.48M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 90.41% |
| 2 | Consumer Staples | 2.45% |
| 3 | Real Estate | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
26
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $2.96M | 0.39% | 18,938 -11,139 | -37% | -$1.74M |
|
|
ITMR
27
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $2.79M | 0.37% | 140,524 | – | – |
|
28
Establishment Labs
ESTA
$1.2B
| $2.52M | 0.33% | +66,921 | New | +$2.52M |
|
29
NeoGenomics
NEO
$1.13B
| $2.47M | 0.33% | +45,951 | New | +$2.47M |
|
30
Rafael Holdings
RFL
$51.6M
| $2.44M | 0.32% | 104,737 | – | – |
|
31
Merck
MRK
$210B
| $2.32M | 0.31% | 28,406 +1,827 | +7% | +$149K |
|
|
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $2.32M | 0.31% | +19,013 | New | +$2.32M |
|
33
AbbVie
ABBV
$372B
| $2.3M | 0.3% | +21,477 | New | +$2.3M |
|
|
EIGR
34
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.28M | 0.3% | 185,719 -286,839 | -61% | -$3.52M |
|
|
CMPS
35
Compass Pathways
CMPS
$424M
| $2.04M | 0.27% | 42,743 -114,239 | -73% | -$5.44M |
|
|
ONCR
36
DELISTED
Oncorus, Inc.
ONCR
| $1.82M | 0.24% | +56,422 | New | +$1.82M |
|
|
PRVB
37
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $1.8M | 0.24% | 105,941 -33,477 | -24% | -$567K |
|
|
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.72M | 0.23% | +7,838 | New | +$1.72M |
|
|
OSH
39
DELISTED
Oak Street Health, Inc.
OSH
| $1.69M | 0.22% | 27,612 -31,280 | -53% | -$1.91M |
|
|
NVRO
40
DELISTED
NEVRO CORP.
NVRO
| $1.66M | 0.22% | 9,589 -2,337 | -20% | -$405K |
|
41
CRISPR Therapeutics
CRSP
$4.71B
| $1.66M | 0.22% | 10,825 +625 | +6% | +$95.7K |
|
|
TRIL
42
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.53M | 0.2% | 103,819 -8,923 | -8% | -$131K |
|
43
Adverum Biotechnologies
ADVM
$64.6M
| $1.47M | 0.19% | 135,992 -228,357 | -63% | -$2.48M |
|
|
KDMN
44
DELISTED
Kadmon Holdings, Inc.
KDMN
| $1.4M | 0.18% | 336,442 +135,601 | +68% | +$563K |
|
45
Viridian Therapeutics
VRDN
$1.5B
| $1.34M | 0.18% | +81,185 | New | +$1.34M |
|
|
PVLA
46
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $1.25M | 0.16% | 500,000 | – | – |
|
47
Scholar Rock
SRRK
$3.14B
| $1.19M | 0.16% | +24,484 | New | +$1.19M |
|
48
Zymeworks
ZYME
$1.12B
| $1.07M | 0.14% | 22,631 -66,602 | -75% | -$3.15M |
|
49
Cardiff Oncology
CRDF
$140M
| $1.02M | 0.14% | 56,909 -224,910 | -80% | -$4.05M |
|
50
Biogen
BIIB
$19.4B
| $955K | 0.13% | 3,899 -7,657 | -66% | -$1.88M |
|